The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Ma H et al. Acta Oncol. 2017 Aug 22:1-7. doi: 10.1080/0284186X.2017.1364868. [Epub ahead of print].
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.
Popat R et al. Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14897. [Epub ahead of print].
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Gupta N et al. Target Oncol. 2017 Aug 12. doi: 10.1007/s11523-017-0524-3. [Epub ahead of print].
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A et al. Am J Hematol. 2017 Aug 11. doi: 10.1002/ajh.24883. [Epub ahead of print].
The Clinical Pharmacology of Elotuzumab.
Passey C et al. Clin Pharmacokinet. 2017 Aug 4. doi: 10.1007/s40262-017-0585-6. [Epub ahead of print].